Monoclonal antibodies in newly diagnosed and smoldering multiple myeloma: an updated review of current clinical evidence.

Monoclonal antibodies in newly diagnosed and smoldering multiple myeloma: an updated review of current clinical evidence. Expert Rev Hematol. 2020 Apr 15;: Authors: Musto P, La Rocca F Abstract Introduction: Monoclonal antibodies (MoAbs) are rapidly changing the therapeutic scenario of multiple myeloma. Most of the available data, however, come from studies performed in patients with relapsed or refractory disease.Area covered: Here, the most recent results from clinical trials that have investigated (or are investigating) efficacy and safety of MoAb as front-line treatments in both transplant-eligible and not-eligible patients with newly diagnosed multiple myeloma (NDMM), as well as in smoldering myeloma, are reviewed. PubMed reported articles before March 28, 2020, and abstracts presented at the last ASCO, ASH, EHA and IMW meetings were considered. Among others, pertinent data regarding daratumumab, isatuximab, elotuzumab and pembrolizumab will be analyzed.Expert opinion: Introduction of MoAbs as first line therapy will likely provide a significant improvement in the clinical outcome of patients with multiple myeloma. This will also require an appropriate re-positioning of salvage therapies. The role of MoAbs in smoldering myeloma appears to be promising, but adequate follow-up is needed. PMID: 32290723 [PubMed - as supplied by publisher]
Source: Expert Review of Hematology - Category: Hematology Tags: Expert Rev Hematol Source Type: research